Do low-carb and ketogenic diets improve cardiometabolic health, even though they often raise LDL?
Low-carbohydrate and ketogenic diets improve cardiometabolic risk markers (weight, triglycerides, HDL, glycemic control), although they frequently raise LDL cholesterol.
This is the crux of the site owner's own situation: low-carb eating tends to improve most metabolic markers while often pushing LDL up. The trial evidence fairly consistently shows better weight, triglycerides, HDL and blood-sugar control on low-carb, but it is not clearly superior to other healthy diets for weight, the LDL rise is real, and there are no long-term hard-outcome trials, so the net cardiovascular effect is genuinely unsettled.
Limited evidence so far: Only one side of this claim is mapped with evidence so far. The opposing case is argued in the steelman above, but its supporting sources are still a documented gap, not an absence of debate.
Evidence balance
Mainstream steelman
Randomized trials show low-carbohydrate diets improve several risk markers - greater weight and fat loss, higher HDL, lower triglycerides, a better triglyceride-to-HDL ratio - and ketogenic care can dramatically improve glycemic control in type 2 diabetes, reducing or eliminating medication. For someone with good triglycerides and HDL and normal glucose, these are meaningful metabolic wins that a single LDL number does not capture. Metabolic health is multi- dimensional, and low-carb moves most dimensions favourably.
Skeptic steelman
The same trials repeatedly show LDL cholesterol rising on low-carb, sometimes sharply, and LDL is the best-established causal driver of atherosclerosis, so improving other markers does not neutralise that. A well-conducted head-to-head trial (DIETFITS) found no significant weight-loss advantage over a healthy low-fat diet, and the strongest ketogenic-diabetes evidence is open-label, non-randomized, and funded by the company selling the programme. None of these trials measured heart attacks or deaths, so favourable markers are a promise of benefit, not proof of it - especially when one key marker moves the wrong way.
Bottom line
Moderate confidenceLow-carb and ketogenic diets do reliably improve weight, triglycerides, HDL and glycemic control, which matters and is not captured by LDL alone. But they frequently raise LDL, are not clearly better than other healthy diets for weight, and have no long-term hard-outcome trials, so they are a reasonable tool for metabolic markers while the net effect of the accompanying LDL rise remains an open and individual question.
This is a clearly-labelled editorial judgment, not a fact. It is written to survive its own skeptic steelman above.
What would change this conclusion
Long-term randomized trials of low-carb or ketogenic diets with hard cardiovascular endpoints (not just markers); or evidence resolving whether the LDL rise on these diets carries the same risk as LDL elevation from other causes, especially in metabolically healthy people.
The evidence (3)
Strongest evidence first. Each card traces to a study and a verbatim quote with a locator.
- MixedHigh tierLipid level (surrogate)
Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion: The DIETFITS Randomized Clinical Trial
JAMA, 2018 - Randomized Controlled Trial
DIETFITS is the strongest head-to-head trial here and it cuts both ways for the claim. Both diets improved most lipid and metabolic markers and lowered blood pressure, insulin, and glucose - but LDL cholesterol rose specifically in the low-carb group, and there was no significant weight-loss advantage for low-carb. It is mixed: it confirms broad metabolic improvement while showing low-carb is not superior and moves LDL the wrong way.
“At 12 months relative to baseline, both diets improved lipid profiles and lowered blood pressure, insulin, and glucose levels, with the exception of low-density lipoprotein cholesterol concentrations, which increased for participants in the healthy low-carbohydrate group.”
Applicability: Healthy versions of both diets; risk markers and weight, no clinical endpoints.
- No significant weight-loss advantage for low-carb over healthy low-fat.
- Partly funded by the Nutrition Science Initiative, a low-carb-leaning funder; the result did not favour low-carb.
- SupportsModerate tierOther biomarker
Effects of low-carbohydrate and low-fat diets: a randomized trial
Annals of Internal Medicine, 2014 - Randomized Controlled Trial
This 12-month randomized trial found the low-carbohydrate diet produced greater weight loss and better cardiometabolic markers than a low-fat diet - higher HDL, lower triglycerides, and a better total-to-HDL cholesterol ratio - with no significant difference in LDL. It supports the claim. It is weighted moderately because it was small (148 participants) and measured risk markers only, with no clinical cardiovascular endpoints.
“At 12 months, participants on the low-carbohydrate diet had greater decreases in weight (mean difference in change, -3.5 kg [95% CI, -5.6 to -1.4 kg]; P = 0.002) ... greater increases in HDL cholesterol level (mean difference in change, 0.18 mmol/L [7.0 mg/dL] [CI, 0.08 to 0.28 mmol/L {3.0 to 11.0 mg/dL}]; P < 0.001) than those on the low-fat diet”
Applicability: Risk markers only; no clinical endpoints; small sample.
- No significant difference in LDL cholesterol between diets.
- Surrogate markers, not heart attacks or deaths.
- SupportsLow tierOther biomarker
Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study
Diabetes Therapy, 2018 - Prospective Cohort
In adults with type 2 diabetes, a ketogenic continuous-care model markedly improved glycemic control (HbA1c fell from 7.6% to 6.3%) and produced large weight loss at one year, as quoted below. It supports the claim that low-carb improves cardiometabolic markers. It is weighted low because it is open-label, non-randomized, and funded by the company that sells the programme - and, importantly, LDL cholesterol rose about 10%, the exact tension this claim is built around.
“HbA1c declined from 59.6 +/- 1.0 to 45.2 +/- 0.8 mmol mol-1 (7.6 +/- 0.09% to 6.3 +/- 0.07%, P < 1.0 x 10-16), weight declined 13.8 +/- 0.71 kg”
Applicability: Type 2 diabetes population; open-label, non-randomized; company-funded.
- LDL cholesterol rose about 10% (P = 5.1 x 10-5).
- Funded by Virta Health, the company selling the intervention; open-label, non-randomized.